


PHARMACEUTICAL 2017

HypGen Inc Rank 300 of 313





PHARMACEUTICAL 2017

HypGen Inc Rank 300 of 313

The relative strengths and weaknesses of HypGen Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of HypGen Inc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 7,046% points. The greatest weakness of HypGen Inc is the variable Cost of Goods Sold, reducing the Economic Capital Ratio by 7,962% points.

The company's Economic Capital Ratio, given in the ranking table, is -1,653%, being 1,237% points below the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	142
Intangible Assets	0
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	-0.52
Other Compr. Net Income	0
Other Expenses	40
Other Liabilities	0.75
Other Net Income	0
Property and Equipment	14
Research and Development	0
Revenues	164
Selling, General and Administrative Expense	14

Output Variable	Value in 1000 USD
Assets	13
Liabilities	0.75
Expenses	195
Stockholders Equity	12
Net Income	-32
Comprehensive Net Income	-32
Economic Capital Ratio	-1,653%